B Coudert
Overview
Explore the profile of B Coudert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Guiu S, Coudert B, Favier L, Arnould L, Fumoleau P
Bull Cancer
. 2010 Feb;
97(3):365-83.
PMID: 20176546
HER2-positive breast cancer accounts for 20 to 25% of breast cancers. The surexpression of this tyrosine-kinase receptor is often associated with a poor prognosis. However, the management and the outcome...
22.
Vegran F, Boidot R, Coudert B, Fumoleau P, Arnould L, Garnier J, et al.
Br J Cancer
. 2009 Sep;
101(8):1357-64.
PMID: 19755993
Background: Resistance to trastuzumab is often observed in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and has been shown to involve multiple potential mechanisms. We examined...
23.
Fumoleau P, Coudert B, Isambert N, Ferrant E
Ann Oncol
. 2007 Oct;
18 Suppl 5:v9-15.
PMID: 17656562
Background: Epothilones are 16-member ring macrolides with antimicrotubule activity that share a similar mechanism of action to the taxanes but have demonstrated potent antiproliferative activity in several different multidrug-resistant and...
24.
Massard C, Voigt J, Laplanche A, Culine S, Lortholary A, Bugat R, et al.
Br J Cancer
. 2007 Sep;
97(7):857-61.
PMID: 17876336
Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase inhibitors are promising new drugs. The aim of this study...
25.
Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al.
Br J Cancer
. 2006 Jan;
94(2):259-67.
PMID: 16404427
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC...
26.
Douillard J, Gervais R, Dabouis G, Le Groumellec A, DArlhac M, Spaeth D, et al.
Ann Oncol
. 2004 Dec;
16(1):81-9.
PMID: 15598943
Background: This phase II trial compared docetaxel-cisplatin (DC) with vinorelbine-cisplatin (VC), both as first-line therapy followed by cross-over at progression to single-agent vinorelbine or docetaxel in advanced non-small-cell lung cancer...
27.
Milojevic K, Cantineau J, Ruiz R, Coudert B, Bataille S, Boutot F, et al.
Am J Emerg Med
. 2004 May;
22(3):238-41.
PMID: 15138974
No abstract available.
28.
Coudert B, Bjarnason G, Focan C, Donato Di Paola E, Levi F
Pathol Biol (Paris)
. 2003 Jul;
51(4):197-200.
PMID: 12852987
The EORTC Chronotherapy Group (CTG) stemmed from the International Organisation for Cancer Chronotherapy(IOCC) in 1996. The IOCC was the first to initiate large scale multicentre international chronotherapy trials, for the...
29.
30.
Dittrich C, Coudert B, Paz-Ares L, Caponigro F, Salzberg M, Gamucci T, et al.
Eur J Cancer
. 2003 Feb;
39(3):330-4.
PMID: 12565985
XR5000 is a tricyclic carboxamide-based cytotoxic agent that binds to DNA by intercalation and stimulates DNA cleavage by inhibition of both topoisomerase I and II. The aim of this study...